135 related articles for article (PubMed ID: 35660482)
1. Diagnosis and Management of Pediatric Papillary Craniopharyngiomas.
Zhao C; Zhou Z; Zhang Y; Qi X; Wang X; Lin D; Liu H; Wang Y; Weng C; Chen J; Hu W; Liao L; Lin Z
World Neurosurg; 2022 Sep; 165():e148-e158. PubMed ID: 35660482
[TBL] [Abstract][Full Text] [Related]
2. BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts.
Schweizer L; Capper D; Hölsken A; Fahlbusch R; Flitsch J; Buchfelder M; Herold-Mende C; von Deimling A; Buslei R
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):733-42. PubMed ID: 25442675
[TBL] [Abstract][Full Text] [Related]
3. Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features.
Yue Q; Yu Y; Shi Z; Wang Y; Zhu W; Du Z; Yao Z; Chen L; Mao Y
J Neurosurg; 2018 Jul; 129(1):27-34. PubMed ID: 28984520
[TBL] [Abstract][Full Text] [Related]
4. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.
Borrill R; Cheesman E; Stivaros S; Kamaly-Asl ID; Gnanalingham K; Kilday JP
Childs Nerv Syst; 2019 Jan; 35(1):169-173. PubMed ID: 30069716
[TBL] [Abstract][Full Text] [Related]
5. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E mutation is a useful marker for differentiating Rathke's cleft cyst with squamous metaplasia from papillary craniopharyngioma.
Kim JH; Paulus W; Heim S
J Neurooncol; 2015 May; 123(1):189-91. PubMed ID: 25820214
[No Abstract] [Full Text] [Related]
7. [Magnetic resonance imaging characteristics and differential diagnosis of common sellar cystic lesions].
Liu H; Lu X; Hang W; Liu G
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Nov; 54(11):819-825. PubMed ID: 31795542
[No Abstract] [Full Text] [Related]
8. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
[TBL] [Abstract][Full Text] [Related]
9. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
[No Abstract] [Full Text] [Related]
10. Preoperative Evaluation of Sellar and Parasellar Macrolesions by [
Tosaka M; Higuchi T; Horiguchi K; Osawa T; Arisaka Y; Fujita H; Tsushima Y; Yoshimoto Y
World Neurosurg; 2017 Jul; 103():591-599. PubMed ID: 28427982
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
[TBL] [Abstract][Full Text] [Related]
12. Optic tract edema in craniopharyngioma as a predictor of BRAFV600E mutation presence.
Taguchi A; Kinoshita Y; Kojima M; Amatya VJ; Tominaga A; Takeshima Y; Arita K; Hiyama E; Yamasaki F; Horie N
Jpn J Clin Oncol; 2023 Apr; 53(5):378-385. PubMed ID: 36702745
[TBL] [Abstract][Full Text] [Related]
13. Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells.
Marucci G; de Biase D; Zoli M; Faustini-Fustini M; Bacci A; Pasquini E; Visani M; Mazzatenta D; Frank G; Tallini G
Pituitary; 2015 Dec; 18(6):905-11. PubMed ID: 26156055
[TBL] [Abstract][Full Text] [Related]
14. Pediatric symptomatic Rathke cleft cyst compared with cystic craniopharyngioma.
Hayashi Y; Kita D; Fukui I; Sasagawa Y; Oishi M; Okajima M; Tachibana O; Nakada M
Childs Nerv Syst; 2016 Sep; 32(9):1625-32. PubMed ID: 27392448
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.
Martinez-Gutierrez JC; D'Andrea MR; Cahill DP; Santagata S; Barker FG; Brastianos PK
Neurosurg Focus; 2016 Dec; 41(6):E2. PubMed ID: 27903124
[TBL] [Abstract][Full Text] [Related]
16. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
Brastianos PK; Taylor-Weiner A; Manley PE; Jones RT; Dias-Santagata D; Thorner AR; Lawrence MS; Rodriguez FJ; Bernardo LA; Schubert L; Sunkavalli A; Shillingford N; Calicchio ML; Lidov HG; Taha H; Martinez-Lage M; Santi M; Storm PB; Lee JY; Palmer JN; Adappa ND; Scott RM; Dunn IF; Laws ER; Stewart C; Ligon KL; Hoang MP; Van Hummelen P; Hahn WC; Louis DN; Resnick AC; Kieran MW; Getz G; Santagata S
Nat Genet; 2014 Feb; 46(2):161-5. PubMed ID: 24413733
[TBL] [Abstract][Full Text] [Related]
17. A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas.
Fujio S; Juratli TA; Arita K; Hirano H; Nagano Y; Takajo T; Yoshimoto K; Bihun IV; Kaplan AB; Nayyar N; Fink AL; Bertalan MS; Tummala SS; Curry WT; Jones PS; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
Neurosurgery; 2019 Aug; 85(2):204-210. PubMed ID: 30481321
[TBL] [Abstract][Full Text] [Related]
18. Imaging Errors in Distinguishing Pituitary Adenomas From Other Sellar Lesions.
Altshuler DB; Andrews CA; Parmar HA; Sullivan SE; Trobe JD
J Neuroophthalmol; 2021 Dec; 41(4):512-518. PubMed ID: 33630780
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of Contrast-Enhanced 3D-FLAIR MR Imaging for Differentiating Rathke Cleft Cyst from Cystic Craniopharyngioma.
Azuma M; Khant ZA; Kitajima M; Uetani H; Watanabe T; Yokogami K; Takeshima H; Hirai T
AJNR Am J Neuroradiol; 2020 Jan; 41(1):106-110. PubMed ID: 31857323
[TBL] [Abstract][Full Text] [Related]
20. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.
Rostami E; Witt Nyström P; Libard S; Wikström J; Casar-Borota O; Gudjonsson O
Acta Neurochir (Wien); 2017 Nov; 159(11):2217-2221. PubMed ID: 28918496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
